Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Recombinant Pbp2a of Methicillin-Resistant S. Aureus Formulation in Alum and Montanide Isa266 Adjuvants Induced Cellular and Humoral Immune Responses With Protection in Balb/C Mice Publisher Pubmed



Mortazavi SS1 ; Haghighat S1 ; Mahdavi M2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Microbiology, Faculty of Advanced Science and Technology, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  2. 2. Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Microbial Pathogenesis Published:2020


Abstract

Staphylococcus aureus is an important cause of both hospital and community acquired infections worldwide. S.aureus can develop multidrug resistance; thus, immunotherapy can be a rational alternative. High level β-lactam resistance of S. aureus has been attributed to the penicillin binding protein 2a (PBP2a). In this study, we assessed the immunogenicity and protectivity of PBP2a formulated in Montanide ISA266 and Alum adjuvants. Recombinant PBP2a with a molecular weight of approximately 13 kDa was expressed and purified by nickel-nitrilotriacetic acid (NI-NTA) affinity chromatography and characterized by SDS-PAGE and Western blot. To investigate the immunogenicity and protective effects of recombinant protein, 20 μg of r-PBP2a in various formulations were subcutaneously injected in different groups. Two booster vaccinations were carried out in two-week intervals and blood samples were collected two weeks after each injection. To determine the type of induced immune response, sera and splenocytes were analyzed by ELISA for total IgG and isotypes (IgG1 and IgG2a) and cytokine secretion (IFN-γ, IL-4, IL-17 and TNF-α), respectively. Three weeks following the last immunization, experimental mice were challenged with 5 × 108 CFU of bacteria intraperitoneally and mortality rate and bacterial load were assessed. Interestingly, analysis of humoral immune responses revealed that administration of r-PBP2a with Montanide ISA266 significantly increased specific IgG responses and also IgG1 isotype compared to alum-adjuvanted vaccine group. Also, r-PBP2a formulation with alum and MontanideISA266 adjuvants raised IFN-γ, IL-4, IL-17 cytokines secretion, and protectivity following experimental challenge. The results of the present study provide evidences for immunogenicity and protectivity of PBP2a protein as a vaccine candidate. © 2019 Elsevier Ltd
Related Docs
View other Related Docs
1. Killed Whole-Cell Staphylococcus Aureus Formulation in Montanide Isa266 and Alum Adjuvants: Different Vaccine Formulations Varied in the Vaccine’S Potency and Efficacy, Immunologic Research (2025)
2. Passive Immunotherapy With Specific Igg Fraction Against Autolysin: Analogous Protectivity in the Mrsa Infection With Antibiotic Therapy, Immunology Letters (2019)
3. Glucomannan As a Polysaccharide Adjuvant Improved Immune Responses Against Staphylococcus Aureus: Potency and Efficacy Studies, Microbial Pathogenesis (2023)
4. Recombinant Pbp2a As a Vaccine Candidate Against Methicillin-Resistant Staphylococcus Aureus: Immunogenicity and Protectivity, Microbial Pathogenesis (2017)
5. Passive Immunization Against Methicillin Resistant Staphylococcus Aureus Recombinant Pbp2a in Sepsis Model of Mice: Comparable Results With Antibiotic Therapy, International Immunopharmacology (2018)
6. Molecular Cloning and Immunogenicity Evaluation of Isde Protein of Methicillin Resistant Staphylococcus Aureus As Vaccine Candidates, Microbial Pathogenesis (2021)
7. Investigating the Effect of Monophosphoryl Lipid a As a Co-Adjuvant on Humoral Immune Response Against Staphylococcus Aureus Infection in a Mouse Model; [بررسی اثر مونوفسفوریل لیپید a به عنوان یک ادجوانت کمکی بر روی پاسخهای ایمنی همورال علیه عفونت ستافیلوکوکوس اورئوس در مدل موشی], Journal of Isfahan Medical School (2023)
8. Monophosphoryl Lipid a As a Co-Adjuvant in Methicillin-Resistant Staphylococcus Aureus Vaccine Development: Improvement of Immune Responses in a Mouse Model of Infection, Immunologic Research (2024)
Experts (# of related papers)
View all Related Experts
Mohammad Hossein Yazdi (9)
Mohammad Reza Pourmand (2)
Other Related Docs
9. Synthetic Selenium Nanoparticles As Co-Adjuvant Improved Immune Responses Against Methicillin-Resistant Staphylococcus Aureus, World Journal of Microbiology and Biotechnology (2023)
10. Recombinant Staphylococcal Antigen-F (R-Scaf), a Novel Vaccine Candidate Against Methicillin Resistant Staphylococcus Aureus Infection: Potency and Efficacy Studies, Microbial Pathogenesis (2019)
11. Preparation and Preclinical Evaluation of Two Novel Staphylococcus Aureus Capsular Polysaccharide 5 and 8-Fusion Protein (Hla-Mntc-Sacol0723) Immunoconjugates, IUBMB Life (2020)
12. A Survey on the Adjuvant Role of Naloxone Alone or Combined With Alum in Vaccination Against Fasciolosis in Balb/C Mice, Acta Parasitologica (2019)
13. The Candidate Antigens to Achieving an Effective Vaccine Against Staphylococcus Aureus, Vaccines (2022)
14. Formulation of a Recombinant Hiv-1 Polytope Candidate Vaccine With Naloxone/Alum Mixture: Induction of Multi-Cytokine Responses With a Higher Regulatory Mechanism, APMIS (2021)
15. Development of Nano-Carriers for Leishmania Vaccine Delivery, Expert Opinion on Drug Delivery (2020)
16. Selenium Nanoparticles As a Co-Adjuvant With Autolysin Recombinant Protein in the Development of a Vaccine Candidate Against Methicillin-Resistant Staphylococcus Aureus, Journal of Isfahan Medical School (2022)
17. High Prevalence of Direct Repeat Unit Types of 10Di, 8 H and 8I Among Methicillin Resistant Staphylococcus Aureus Strains With Staphylococcal Cassette Chromosome Mec Type Iiia Isolated in Tehran, Iran, Antimicrobial Resistance and Infection Control (2019)
18. Formulation of Hbs Antigen in Montanide Isa266 Shows Superiority to Commercial Hbsag Vaccine in the Induction of Humoral Immune Responses, Gastroenterology and Hepatology from Bed to Bench (2019)
19. Improvement of the Inactivated Sars-Cov-2 Vaccine Potency Through Formulation in Alum/Naloxone Adjuvant; Robust T Cell and Anti-Rbd Igg Responses, Iranian Journal of Basic Medical Sciences (2022)